Cancer Center Clínica Universidad de Navarra (CCUN)
Centro clínico de la Universidad de Navarra
María D.
Odero
Catedrática de Universidad
Publicacións nas que colabora con María D. Odero (57)
2023
-
Activation of the PP2A-B56α heterocomplex synergizes with venetoclax therapies in AML through BCL2 and MCL1 modulation
Blood, Vol. 141, Núm. 9, pp. 1047-1059
-
Regulation and role of the PP2A-B56 holoenzyme family in cancer
Biochimica et Biophysica Acta - Reviews on Cancer, Vol. 1878, Núm. 5
-
Set Protein Is Involved in FLT3 Membrane Trafficking
Cancers, Vol. 15, Núm. 8
2021
-
Endogenous retroelement activation by epigenetic therapy reverses the warburg effect and elicits mitochondrial-mediated cancer cell death
Cancer Discovery, Vol. 11, Núm. 5, pp. 1268-1285
-
Tumor cells in light-chain amyloidosis and myeloma show distinct transcriptional rewiring of normal plasma cell development
Blood, Vol. 138, Núm. 17, pp. 1583-1589
2020
-
A new regulatory mechanism of protein phosphatase 2A activity via SET in acute myeloid leukemia
Blood Cancer Journal, Vol. 10, Núm. 1
-
A novel FTY720 analogue targets SET-PP2A interaction and inhibits growth of acute myeloid leukemia cells without inducing cardiac toxicity
Cancer Letters, Vol. 468, pp. 1-13
2017
-
MYC-dependent recruitment of RUNX1 and GATA2 on the SET oncogene promoter enhances PP2A inactivation in acute myeloid leukemia
Oncotarget, Vol. 8, Núm. 33, pp. 53989-54003
2016
-
Protein phosphatase 2A as a therapeutic target in acute myeloid leukemia
Frontiers in Oncology, Vol. 6, Núm. APR
2015
-
CIP2A high expression is a poor prognostic factor in normal karyotype acute myeloid leukemia
Haematologica
-
GATA2 germline mutations impair GATA2 transcription, causing haploinsufficiency: Functional analysis of the p.Arg396Gln mutation
Journal of Immunology, Vol. 194, Núm. 5, pp. 2190-2198
-
Lipid nanosystems enhance the bioavailability and the therapeutic efficacy of FTY720 in acute myeloid leukemia
Journal of Biomedical Nanotechnology, Vol. 11, Núm. 4, pp. 691-701
2014
-
Effect of FTY720 on the SET-PP2A complex in acute myeloid leukemia; SET binding drugs have antagonistic activity
Leukemia
-
Hypermethylation of the alternative AWT1 promoter in hematological malignancies is a highly specific marker for acute myeloid leukemias despite high expression levels
Journal of Hematology and Oncology, Vol. 7, Núm. 1
2013
-
Edelfosine lipid nanosystems overcome drug resistance in leukemic cell lines
Cancer Letters, Vol. 334, Núm. 2, pp. 302-310
-
Functional characterization of the promoter region of the human EVI1 gene in acute myeloid leukemia: RUNX1 and ELK1 directly regulate its transcription
Oncogene, Vol. 32, Núm. 16, pp. 2069-2078
2012
-
Epigenetic regulation of miRNA genes in acute leukemia
Leukemia, Vol. 26, Núm. 3, pp. 395-403
-
Mutation patterns of 16 genes in primary and secondary acute myeloid leukemia (AML) with normal cytogenetics
PLoS ONE, Vol. 7, Núm. 8
-
Overexpression of GATA2 predicts an adverse prognosis for patients with acute myeloid leukemia and it is associated with distinct molecular abnormalities
Leukemia
-
The role of the GATA2 transcription factor in normal and malignant hematopoiesis
Critical Reviews in Oncology/Hematology, Vol. 82, Núm. 1, pp. 1-17